**Effect of Rosuvastatin on Myocardial Apoptosis in Hypertensive Rats Through SIRT1/NF-κB Signaling Pathway**

Xiangqian Ren, Yi Wang, Lin Han, Zhenzhen Sun, Bin Yuan*

Department of Cardiology, Anning Branch, 940 Hospital of the Joint Service support Force of the Chinese People’s Liberation Army, Gansu, 730070, China

**ARTICLE INFO**

**Original paper**

Article history:
Received: January 11, 2022
Accepted: March 17, 2022
Published: April 30, 2022

**Keywords:** rosuvastatin, SIRT1/NF-κB signaling pathway, hypertensive rats, myocardial apoptosis

**ABSTRACT**

The study aimed to observe the effect of rosuvastatin on myocardial apoptosis in hypertensive rats through the silent information regulator 1 (SIRT1)/nuclear factor-xB (NF-xB) signaling pathway. The spontaneously hypertensive rat (SHR) model was established, and the rats were randomly divided into the SHR group, Rosuvastatin group and Control group. The blood pressure, creatine kinase (CK) and other myocardial indexes in each group were determined using magnetic resonance imaging (MRI) and echocardiography (ECC), and tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in myocardial tissues were detected via enzyme-linked immunosorbent assay (ELISA). Moreover, the apoptosis level of myocardial tissues was detected using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining. Finally, the expression levels of the SIRT1/NF-κB signaling pathway and apoptosis genes and proteins in myocardial tissues in each group were detected via quantitative polymerase chain reaction (qPCR) and Western blotting. In the SHR group, the blood pressure, the levels of serum creatinine (CR) and CK were increased (p<0.05). In the SHR group, both fractional shortening (FS%) and ejection fraction (EF%) were obviously lower than those in the control group (p<0.05), while both left ventricular end-systolic diameter (LVEDd) and left ventricular end-systolic diameter (LVESd) were higher than those in the control group (p<0.05), and the levels of TNF-α, IL-6 and myeloperoxidase (MPO) were increased (p<0.05). The number of apoptotic cells in myocardial tissues in the SHR group was larger than that in the other two groups (p<0.05). In the SHR group, the expression levels of Caspase3 and NF-κB were remarkably higher than those in the Rosuvastatin group (p<0.05), while the expression levels of Bcl-2 and SIRT1 were remarkably lower than those in the Rosuvastatin group (p<0.05). Rosuvastatin can inhibit myocardial apoptosis in hypertensive rats through up-regulating SIRT1 and down-regulating NF-κB.

**Introduction**

Arterial hypertension has become a major health problem due to its high morbidity rate and cardiovascular risk accompanied, which has been identified as a major risk factor for cardiac death, seriously affecting the health and quality of life of patients (1). Hypertension refers to the increase in systolic arterial pressure or diastolic pressure (≥140/90 mmHg) in a resting state, which is the major cause of cardiomyopathy (2, 3). Human primary hypertension often leads to cardiac remodeling, ventricular hypertrophy and congestive heart failure (4) and causes cardiac dysfunction, further resulting in poor clinical prognosis, ultimately causing severe cardiovascular diseases (5). Cardiovascular diseases threaten the health and even cause death in the world.

The incidence rates of heart failure, arrhythmia and coronary heart disease in patients with hypertension are 8-10 times that in normal people (6). Therefore, exploring the pathogenesis of hypertension is of great significance in the prevention and treatment of cardiovascular diseases such as heart failure. However, the treatment strategies and pathogenesis of hypertensive cardiomyopathy have not been perfected yet. Currently, only several related factors have been discovered by researchers (7, 8). Myocardial hypertrophy and apoptosis are key pathological changes in cardiac dysfunction. It is reported that in the pathophysiological process, myocardial apoptosis is one of the causes of the decline in myocardial mass (9). However, the specific role of apoptosis in end-stage hypertensive heart disease remains unclear and

*Corresponding author. E-mail: yuhuicuo35838@163.com

Cellular and Molecular Biology, 2022, 68(4): 194-201
is poorly understood, and it is regulated by a variety of cell growth factors.

Silent information regulator 1 (SIRT1) plays an important role in cell homeostasis, and the SIRT1 signaling pathway is essential for the anti-apoptotic property in diseases (10). Recent studies have demonstrated that SIRT1 has an important role in DNA damage repair, inhibition of apoptosis, oxidative stress, etc. Under ischemic or hypoxic conditions, SIRT1 can deacetylate to enhance the resistance of cells to oxidative stress (11). Multiple signaling pathways are involved in the inflammatory response and tissue damage. Nuclear factor-κB (NF-κB) can control many biological processes, such as inflammation and apoptosis (12). A study has shown that NF-κB can significantly promote the production of tumor necrosis factor-α (TNF-α), causing toxicity of TNF-α to the body (13). Therefore, the dysregulation of the NF-κB signal transduction mechanism is a potential cause of various diseases (14). As an inflammatory switch or sensor, NF-κB produces the inflammatory response to various stimuli and initiates inflammatory genes. The nuclear transcription factor can be activated by many factors, leading to the activation of NF-κB (15). Therefore, it is important to understand the correlation between NF-κB and various downstream signaling molecules. In the case of dysregulation, NF-κB will be the driving force of diseases. However, the specific mechanism of the effect of the SIRT1/NF-κB signaling pathway on hypertension and myocardial apoptosis remains unclear. In this experiment, therefore, the effects of the SIRT1/NF-κB signaling pathway on myocardial apoptosis and inflammation in hypertension were verified using a variety of molecular methods, hoping to provide an experimental and theoretical basis for the prevention and treatment of myocardial apoptosis in hypertension through the SIRT1/NF-κB signaling pathway.

The present study aims to explore the effect of rosuvastatin on myocardial apoptosis in hypertensive rats and its influence on the SIRT1/NF-κB signaling pathway. In this study, the effect of rosuvastatin on myocardial apoptosis in hypertensive rats was clarified using in vivo experiments and various molecular biological techniques, the cardiac function indexes and pathway-related protein expressions were detected after intervention with rosuvastatin in the hypertensive rat model, and the effect of rosuvastatin on myocardial apoptosis in rats through the SIRT1/NF-κB pathway was determined, so as to provide important experimental support for the treatment of myocardial apoptosis in hypertension with rosuvastatin, as well as theoretical and experimental references for the subsequent research and development of new drugs for myocardial apoptosis in hypertensive rats.

Materials and methods

Commonly used reagents and consumables

TNF-α and interleukin-6 (IL-6) enzyme-linked immunosorbent assay (ELISA) kits (Nanjing Jiancheng Bioengineering Institute), TRIzol reagent, DEPC-treated water, SuperScript III RT kit and SYBR quantitative polymerase chain reaction (qPCR) Mix (ABI), RIPA lysis buffer (Beyotime), loading buffer, protease inhibitor and BCA protein concentration assay kit (Bioharph), β-actin and secondary antibodies (Boster Biological Technology Co., Ltd.), primary antibodies (Santa), tissue homogenizer and electrophoresis apparatus (Bio-Rad), microplate reader (Thermo), 2500 gel imager (Bio-Rad, USA), and qPCR instrument (7900 Fast, Applied Biosystems).

Animal modeling and grouping

Twenty male Wistar spontaneously hypertensive rats (SHRs) aged 8 weeks old and weighing about 250 g were randomly divided into the SHR group (n=10) and Rosuvastatin group (10 mg/kg/d, n=10) after adaptive feeding. Another 10 Wistar rats were used as the Control group. The experimental scheme was approved by the Laboratory Animal Ethics Committee, and all animal operations were performed in accordance with the regulations in the NIH Laboratory Animal Guide. The rats in each group were fed for 2 weeks. After the trial period, the blood and myocardial tissue samples were collected from rats in each group, and one portion of tissues was stored in 4% paraformaldehyde for hematoxylin-eosin (HE) staining and the other one was stored in a refrigerator at -80°C to detect the expression levels of genes and proteins.

The study was approved by the ethics committee of 940 Hospital of the Joint Service support Force of the Chinese People’s Liberation Army.
Detection of arterial blood pressure and myocardial function of rats

After the experiment, the systolic blood pressure and diastolic blood pressure (mmHg) of the caudal artery were measured using a sphygmomanometer in accordance with the instructions of the instrument. To predict the occurrence of myocardial apoptosis in hypertensive rats in clinical practice in advance and provide important references for early diagnosis, the myocardial function indexes creatine kinase (CK) and creatinine (CR) were detected. The blood was routinely drawn from rats in each group and centrifuged at 2000 g for 10 min under low temperature, and the serum separated was collected, followed by detection using a full-automatic biochemical analyzer.

Determination of cardiac physiological function indexes

To observe whether hypertension induces myocardial dysfunction, the left ventricular function was determined through magnetic resonance imaging (MRI) and echocardiography (ECG) under the transducer frequency of 10 MHz, including left ventricular end-diastolic diameter (LVEDd), left ventricular end systolic diameter (LVESd), ejection fraction (EF) and fractional shortening (FS), according to the instructions of the instrument.

Detection of inflammatory factors in each group

After the rats were anesthetized and sacrificed, the myocardial tissues were harvested and washed with normal saline. Then 0.5 g of myocardial tissues were taken, smashed using the homogenizer with tissue lysis buffer prepared already, and centrifuged at 1500 g for 15 min. Then the supernatant was collected to detect the changes in levels of myeloperoxidase (MPO), IL-6 and TNF-α. Finally, the absorbance of MPO was plotted, based on which the changes in content were analyzed according to the instructions.

HE staining

The rats were sacrificed via dislocation at one time, and the heart was isolated and fixed with 4% paraformaldehyde at 4°C for 48 h. The tissues were washed with running water, dehydrated with ethanol at different concentrations and embedded in paraffin. Then they were routinely sliced into 4-5 μm-thick sections, deparaffinized and hydrated with 95%, 90%, 80%, 75% and 50% ethanol. Finally, the pathological changes in myocardial tissues were observed under a light microscope.

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) apoptosis assay

The myocardial apoptosis of paraffin sections was detected using the TUNEL apoptosis assay kit (Roche), as follows: The tissues were fixed, rinsed, infiltrated with 0.1% Triton X-100 and prepared into paraffin sections, followed by labeling reaction of sealed sections using the fluorescence developer. The FITC-labeled TUNEL-positive cells were observed under a fluorescence microscope, and the TUNEL-positive cells were counted in 10 fields of view.

QRT-PCR

The total RNA was extracted using TRIzol (Invitrogen) from myocardial tissues and reversely transcribed into cDNA (the use of isopropanol was noted) after the RNA purity and concentration were detected qualified. The primer amplification was performed using the system (20 μL): 2 μL of cDNA, 10 μL of the mix, 2 μL of primers and 6 μL of ddH2O, for a total of 40 cycles. Then the PCR amplification was performed: pre-denaturation at 95°C for 2 min, 94°C for 20 s, 60°C for 20 s and 72°C for 30 s, for a total of 40 cycles. The primer sequences of target genes and the internal reference β-actin were designed according to those in the GenBank (Table 1). The expression levels of target genes were detected via qRT-PCR. The mRNA expression level in myocardial tissues in each group was calculated using 2^ΔΔCt.

Table 1. PCR primers used in this experiment

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>F:5'-CAGTGGCAGCCGCTCGTCTCAT-3'</td>
</tr>
<tr>
<td></td>
<td>R:5'-AGGGCCCATCCAAGTCTTC-3'</td>
</tr>
<tr>
<td>Caspase3</td>
<td>F:5'-CTACCCGCACCCGGTTACTAT-3'</td>
</tr>
<tr>
<td></td>
<td>R:5'-TCTGGGTATAACAGACTGAGG-3'</td>
</tr>
<tr>
<td>Bcl2</td>
<td>F:5'-GGTGCTCTTGGAGATCTCTGG-3'</td>
</tr>
<tr>
<td></td>
<td>R:5'-CCATCGATCTTCCTCAGAGTCTCC-3'</td>
</tr>
<tr>
<td>SIRT1</td>
<td>F:5'-GCACAGCACTTGCCCTGAT-3'</td>
</tr>
<tr>
<td></td>
<td>R:5'-GTGCTACTGCTTCACTCT-3'</td>
</tr>
<tr>
<td>NF-κB</td>
<td>F:5'-CTGAACAGGGGATACATCCTTG-3'</td>
</tr>
<tr>
<td></td>
<td>R:5'-GAAAGTCCATGTCCGCAAT-3'</td>
</tr>
</tbody>
</table>
Western blotting

The myocardial tissues were cut into pieces, weighed and added with RIPA lysis buffer (100 mg: 1 mL) for tissue homogenization. The protein was extracted, and the protein concentration was calculated using the BCA protein assay kit. Then Western blotting was performed: The gel was prepared for protein loading and electrophoresis, and the protein was transferred onto a membrane, sealed, incubated with the primary antibody overnight and incubated again with the secondary antibody for 1 h. The freshly prepared ECL mixture was added, and the color was developed in a darkroom. The protein band was scanned and quantified using the Odyssey scanner, and the level of protein to be detected was corrected using GAPDH. Finally, the Western blotting bands were quantified using Image Lab software. The protein expression in each group was calculated.

Statistical analysis

All raw data in the experiments were statistically analyzed using SPSS 20.0 software, and multiple comparisons were performed. The experimental results were expressed as mean ± standard deviation (χ±s). p<0.05 suggested that the difference was statistically significant. The bar graph was plotted using GraphPad Prism 7.0.

Results and discussion

Myocardial function and blood pressure

As shown in Table 2, both systolic blood pressure and diastolic blood pressure in the SHR group were significantly higher than those in the Control group (p<0.05). According to the detection results of myocardial function indexes, the levels of serum CR and CK were significantly higher in the SHR group than those in the Control group (p<0.05), while they significantly declined in the Rosuvastatin group (p<0.05), suggesting that the hypertensive rat model is successfully established, with significantly increased myocardial function indexes, which can provide important references for early diagnosis.

Cardiac function indexes of rats

In the SHR group, both FS (%) and EF (%) were evidently lower than those in the Control group, while both LVEDd and LVESd were higher than those in the Control group (p<0.05) (Table 3), indicating that the cardiac functions of hypertensive rats are changed.

Detection results of inflammatory factors in each group

As shown in Table 4, the levels of inflammatory factors TNF-α, IL-6 and MPO were evidently increased in the SHR group compared with those in the other two groups, while they declined in the Rosuvastatin group (p<0.05), suggesting that a large number of inflammatory factors are produced in myocardial tissues in hypertensive rats, which further indicates the development of myocardial injury.

Table 2. Blood pressure and serum biochemical detection results

<table>
<thead>
<tr>
<th>Group</th>
<th>Systolic blood pressure (mmHg)</th>
<th>Diastolic blood pressure (mmHg)</th>
<th>CK (U/L)</th>
<th>CR (μmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>94.9±2.5</td>
<td>76.9±3.1</td>
<td>70.1±1.0</td>
<td>20.7±0.5</td>
</tr>
<tr>
<td>SHR group</td>
<td>158.3±4.3</td>
<td>118.5±5.5</td>
<td>186.9±0.8</td>
<td>85.5±2.7a</td>
</tr>
<tr>
<td>Rosuvastatin group</td>
<td>100.5±2.7</td>
<td>85.6±2.5</td>
<td>86.6±0.8</td>
<td>27.3±4.5</td>
</tr>
</tbody>
</table>

Note: Both systolic blood pressure and diastolic blood pressure in the SHR group are significantly higher than those in the Control group (p<0.05). The levels of serum CR and CK are significantly higher in the SHR group than those in the Control group (p<0.05), while they significantly decline in the Rosuvastatin group (p<0.05). *p<0.05 vs. Control group, †p<0.05 vs. SHR group

Table 3. Cardiac function indexes of rats

<table>
<thead>
<tr>
<th>Group</th>
<th>LVEDd (mm)</th>
<th>LVESd (mm)</th>
<th>FS (%)</th>
<th>EF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>4.09±0.85</td>
<td>4.38±0.29</td>
<td>68±3.4</td>
<td>58.7±3.4</td>
</tr>
<tr>
<td>SHR group</td>
<td>9.95±0.55</td>
<td>7.9±0.76</td>
<td>42±3.6</td>
<td>36.8±2.4</td>
</tr>
<tr>
<td>Rosuvastatin group</td>
<td>5.8±0.27</td>
<td>5.2±0.19</td>
<td>60±2.7</td>
<td>52.6±1.1</td>
</tr>
</tbody>
</table>

Note: In the SHR group, both FS (%) and EF (%) are lower than those in the Control group, while both LVEDd and LVESd are higher than those in the Control group (p<0.05). *p<0.05 vs. Control group, †p<0.05 vs. SHR group

Table 4. Inflammatory levels of TNF-α, IL-6 and MPO in Control, SHR and Rosuvastatin groups

<table>
<thead>
<tr>
<th>Group</th>
<th>IL-6 (ng/L)</th>
<th>TNF-α (fmol/mL)</th>
<th>MPO (μg/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>80.1±4.2</td>
<td>41.1±3.3</td>
<td>2.6±1.2</td>
</tr>
<tr>
<td>SHR group</td>
<td>160.5±6.4</td>
<td>89.6±6.3 4</td>
<td>14.6±1.4</td>
</tr>
<tr>
<td>Rosuvastatin group</td>
<td>89.8±5.04</td>
<td>50.4±4.5</td>
<td>4.8±1.1</td>
</tr>
</tbody>
</table>

Note: The levels of TNF-α, IL-6 and MPO are increased in the SHR group, while the decline in the Rosuvastatin group. *p<0.05 vs. SHR group, †p<0.05 vs. Control group

HE staining

The morphological changes in myocardial tissues in each group were detected using HE staining. As shown in Figure 1, the myocardial cells were arranged disorderly with thickening of muscle fibers and inflammatory cell infiltration in SHR group (A), and the myocardial cells had basically the normal structure...
and ordered arrangement with mild pathological changes in Rosuvastatin group (B).

Figure 1. HE staining. The myocardial cells are arranged disorderly with thickening of muscle fibers and inflammatory cell infiltration in the SHR group (A, 10×), and the myocardial cells have basically the normal structure and ordered arrangement with mild pathological changes in the Rosuvastatin group (B, 10×).

TUNEL staining

The apoptosis level of myocardial tissues was detected using TUNEL staining. As shown in Figure 2, there was almost no myocardial apoptosis in the Control group (A), but a large number of apoptotic myocardial cells were found in the SHR group (B), and myocardial apoptosis declined after rosuvastatin treatment in Rosuvastatin group (C).

Figure 2. The apoptosis level is detected using TUNEL staining. A large number of apoptotic myocardial cells are found in the SHR group, and myocardial apoptosis declines in the Rosuvastatin group. A: Control group. B: SHR group. C: Rosuvastatin group.

Apoptosis- and pathway-related gene expressions detected using RT-PCR

In the Rosuvastatin group, the Caspase3 and NF-κB genes were remarkably reduced (p<0.05) and the Bcl-2 and SIRT1 genes were remarkably raised (p<0.05), while these genes showed the opposite trends in the SHR group (Figure 3), demonstrating that myocardial apoptosis is inhibited after rosuvastatin treatment.

Figure 3. Expression levels of apoptosis- and pathway-related genes. In the Rosuvastatin group, the Caspase3 and NF-κB genes are remarkably decreased (p<0.05) and the Bcl-2 and SIRT1 genes are remarkably increased (p<0.05), while these genes show the opposite trends in the SHR group. *p<0.05 vs. Control group, †p<0.05 vs. SHR group

Western blotting results

In the Rosuvastatin group, the expression levels of Bcl-2 and SIRT1 were remarkably increased (p<0.05) and the NF-κB protein expression was remarkably decreased (p<0.05), while the protein expressions in the SHR group showed the opposite trends (Figure 4), indicating that myocardial apoptosis is suppressed after rosuvastatin treatment.

Figure 4. Expression levels of apoptosis- and pathway-related proteins. A: Expression levels of apoptosis- and pathway-related proteins by Western blot. B: Quantification analysis of Western blot result. In the Rosuvastatin group, the expression levels of Bcl-2 and SIRT1 are remarkably increased (p<0.05) and the NF-κB protein expression is remarkably decreased (p<0.05), while the protein expressions in the SHR group show the opposite trends. *p<0.05 vs. Control group, †p<0.05 vs. SHR group
Both systolic blood pressure and diastolic blood pressure will be significantly increased when hypertension occurs. Hypertension is the most important cause of cardiomyopathy, and human primary hypertension often leads to cardiac remodeling, ventricular hypertrophy and congestive heart failure, and causes cardiac dysfunction, further resulting in severe cardiovascular diseases (16). In the present study, the SHR model was established, and the blood pressure and cardiac function were detected to observe the effect of hypertension on the myocardium. The results showed that both systolic blood pressure and diastolic blood pressure in the SHR group were significantly higher than those in the Control group. According to the detection results of myocardial function indexes, the levels of serum CR and CK were significantly higher in the SHR group than those in the Control group, while they significantly declined in the Rosuvastatin group, suggesting that the hypertensive rat model is successfully established, with significantly increased myocardial function indexes, which can provide important references for early diagnosis. In addition, in SHR group, both FS (%) and EF (%) were lower than those in the Control group, while both LVEDd and LVESd were obviously higher than those in the Control group, indicating that the cardiac functions of hypertensive rats are changed. According to HE staining, the myocardial cells were arranged orderly in the Control group, the myocardial cells were arranged disorderly with thickening of muscle fibers and inflammatory cell infiltration in the SHR group, and the myocardial cells had basically the normal structure and ordered arrangement with mild pathological changes in Rosuvastatin group, demonstrating that hypertension will cause cardiac dysfunction.

Apoptosis plays an important role in maintaining a stable number of myocardial cells, which can remove harmful substances in cells. In the case of lethal threats, the apoptotic reflex will be quickly activated, which, as the defender of the body, supplies energy to the production and metabolism of subcellular structure (17). However, the mechanism of apoptosis in the physiological metabolism of organisms has not been clearly determined. In the present study, the apoptosis level of myocardial tissues was detected using TUNEL staining. It was found that there was almost no myocardial apoptosis in the Control group, but a large number of apoptotic myocardial cells were found in the SHR group, and myocardial apoptosis obviously declined after rosuvastatin treatment in the Rosuvastatin group. Apoptosis is regulated by apoptosis-related genes and proteins, including Bcl-2 and Caspase3(18). The results of RT-PCR in this study manifested that the Caspase3 expression was remarkably decreased and the Bcl-2 expression was remarkably increased in the Rosuvastatin group, while these gene expressions showed the opposite trends in the SHR group, demonstrating that myocardial apoptosis is inhibited after rosuvastatin treatment, which is consistent with the findings of studies of Qian and Leo et al (19, 20). With the deepening of research on hypertensive cardiomyopathy, the progression of hypertension has been gradually determined, and the clinicopathologic process of hypertension mainly includes the increased cytokines and elevated inflammatory mediators (21), and such inflammatory factors as TNF-α and IL-6 released can activate the downstream key anti-inflammatory transcription factor NF-κB. As a transcription factor, NF-κB promotes the production of TNF-α and the expression of inflammatory cytokines (22-24), whereas SIRT1 can inhibit the activation of inflammatory factors and NF-κB signals (25).

Conclusions
In this study, the levels of inflammatory factors TNF-α, IL-6 and MPO were detected, and it was found that their levels of them were evidently increased in the SHR group compared with those in the other two groups, while they declined in the Rosuvastatin group, suggesting that a large number of inflammatory factors are produced in myocardial tissues in hypertensive rats, which further indicates the development of myocardial injury. Moreover, it was found in gene detection that the NF-κB expression was remarkably decreased and the SIRT1 expression was remarkably increased in the Rosuvastatin group, while these gene expressions showed the opposite trends in the SHR group. In the SHR group, the NF-κB protein expression was evidently increased and the SIRT1 protein expression was decreased, suggesting that the activation of the NF-κB pathway is inhibited and the expression of SIRT1 is promoted after rosuvastatin treatment, thereby benefitting the recovery of myocardial apoptosis in hypertension.
similar to the above study results. To sum up, rosvastatin can improve myocardial apoptosis in hypertension by activating the SIRT1 pathway and inhibiting the NF-κB pathway. Despite the conclusion being confirmed, there are still some deficiencies in this experiment. For example, the mechanism of the effect of rosvastatin on myocardial apoptosis in hypertension was not proved through the cell culture technique. In subsequent studies, therefore, more cell lines can be introduced to explore the specific protective effect of rosvastatin in myocardial apoptosis using more molecular biological techniques.

In conclusion, rosvastatin may exert a protective effect against myocardial apoptosis in hypertension, which can alleviate inflammatory cell infiltration and myocardial apoptosis, and such an effect is realized mainly through mediating SIRT1/NF-κB. The present study provides a theoretical basis for the prevention and treatment of myocardial apoptosis in hypertension and new ideas for subsequent further research as well as research ideas for subsequent development of new drugs.

Acknowledgments
Not applicable.

Interest conflict
The authors declare that they have no conflict of interest.

Funding
No funding was received

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
XR wrote the manuscript. ZR and YW were responsible for the construction of the animal model. LH and ZS performed a TUNEL apoptosis assay and PCR. BY helped with Western blot. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the ethics committee of 940 Hospital of the Joint Service support Force of the Chinese People’s Liberation Army.

Consent for publication
Not applicable.

References
12. Vallabhapurapu S, Karin M: Regulation and function of NF-kappaB transcription factors in...


